18889881171
Kalkine 0
countryflagUS

Adaptive Biotechnologies Corp

Healthcare US ADPT

10.49USD
0.17(1.65%)

Last update at 2025-06-16T14:52:00Z

Day Range

10.1410.52
LowHigh

52 Week Range

2.287.07
LowHigh

Fundamentals

  • Previous Close 10.32
  • Market Cap950.41M
  • Volume180978
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-146.94600M
  • Revenue TTM177.28M
  • Revenue Per Share TTM1.21
  • Gross Profit TTM -13.65700M
  • Diluted EPS TTM-1.34

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -200.36800M -207.29800M -146.22700M -68.60600M -46.44700M
Minority interest 0.18M -0.01900M - - 0.00000M
Net income -142.46400M -205.61100M -139.63700M -58.82100M -46.44700M
Selling general administrative 88.53M 74.50M 49.54M 30.33M 20.41M
Selling and marketing expenses 95.60M 95.47M 61.36M 38.45M 24.49M
Gross profit 127.40M 105.04M 75.85M 62.80M 35.99M
Reconciled depreciation 20.92M 13.95M 8.47M 7.79M 6.00M
Ebit -200.18600M -208.96600M -152.81700M -78.39100M -49.75600M
Ebitda -194.43100M -207.26700M -151.11400M -76.69300M -43.75600M
Depreciation and amortization 5.75M 1.70M 1.70M 1.70M 6.00M
Non operating income net other 4.06M 1.67M 6.59M - -
Operating income -200.18600M -208.96600M -152.81700M -78.39100M -49.75600M
Other operating expenses 385.49M 363.31M 251.20M 163.46M 105.42M
Interest expense 4.24M 1.67M 0.00000M 0.00000M 0.00000M
Tax provision - 0.00000M 0.00000M - -
Interest income 4.06M 1.67M 6.59M 9.79M 3.31M
Net interest income -0.18200M 1.67M 6.59M 9.79M 3.31M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -57.90400M -1.68700M -6.59000M -9.78500M 3.31M
Total revenue 185.31M 154.34M 98.38M 85.07M 55.66M
Total operating expenses 327.58M 314.01M 228.67M 141.19M 85.75M
Cost of revenue 57.91M 49.30M 22.53M 22.27M 19.67M
Total other income expense net -0.18200M 1.67M 6.59M 9.79M 3.31M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -200.36800M -207.29800M -146.22700M -68.60600M -46.44700M
Net income applicable to common shares -200.19100M -207.27900M -146.22700M -69.57000M -46.34500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 661.13M 856.62M 923.34M 1116.41M 912.30M
Intangible assets 5.13M 6.83M 8.53M 10.22M 11.93M
Earning assets - - - - -
Other current assets 10.37M 9.44M 13.02M 14.54M 14.08M
Total liab 352.86M 392.52M 319.24M 373.15M 341.26M
Total stockholder equity 308.40M 464.17M 603.99M 743.27M 571.04M
Deferred long term liab - - - - -
Other current liab 22.28M 28.36M 24.98M 25.11M 12.87M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -1144.33200M -919.08200M -718.89100M -511.61200M -365.47800M
Other liab - 183.96M 98.75M 163.62M 226.34M
Good will 118.97M 118.97M 118.97M 118.97M 118.97M
Other assets - 4.46M 3.01M 2.74M 39.53M
Cash 65.06M 90.03M 139.06M 123.44M 96.58M
Cash and equivalents - - - - -
Total current liabilities 88.02M 109.79M 113.81M 105.20M 78.31M
Current deferred revenue 48.63M 64.11M 80.46M 73.32M 60.99M
Net debt 164.37M 17.97M -27.32500M -15.57400M -59.96900M
Short term debt 9.38M 9.23M 5.05M 3.53M -
Short long term debt - - - - -
Short long term debt total 229.43M 108.00M 111.74M 107.86M 36.61M
Other stockholder equity 1452.50M 1387.35M 1324.01M 1253.97M 23.53M
Property plant equipment - 83.45M 85.26M 39.69M 23.75M
Total current assets 410.19M 562.15M 402.75M 726.91M 612.69M
Long term investments - 0.00000M 217.15M 118.53M 105.44M
Net tangible assets - 338.37M 476.49M 614.07M 440.14M
Short term investments 281.34M 408.17M 214.00M 564.83M 480.29M
Net receivables 38.97M 40.06M 17.41M 10.05M 12.68M
Long term debt - - - - -
Inventory 14.45M 14.45M 19.26M 14.06M 9.07M
Accounts payable 7.72M 8.08M 3.31M 3.24M 4.45M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - -0.06700M 0.11M - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.21M -4.11600M -1.13700M 0.89M 0.67M
Additional paid in capital - - - - -
Common stock total equity - 0.01M 0.01M 0.01M 0.01M
Preferred stock total equity - - - - -
Retained earnings total equity - -919.08200M -718.89100M -511.61200M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -1.53700M 4.46M 3.01M 2.74M 2.92M
Deferred long term asset charges - - - - -
Non current assets total 250.95M 294.47M 520.60M 389.50M 299.61M
Capital lease obligations 98.77M 108.00M 111.74M 107.86M 36.61M
Long term debt total - - - - 36.61M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 2.90M 242.96M -98.24100M -470.49700M 7.04M
Change to liabilities 7.11M 3.94M 7.50M 273.08M 1.54M
Total cashflows from investing activities 2.90M 181.21M -117.04400M -481.69700M 0.74M
Net borrowings - - - - 0.00000M
Total cash from financing activities 132.26M 27.15M 293.59M 319.92M 1.25M
Change to operating activities -0.33000M 9.53M -2.52400M -9.09500M -0.98800M
Net income -200.36800M -207.29800M -146.22700M -68.60600M -46.44700M
Change in cash -48.77500M 15.63M 26.86M 43.62M -30.27500M
Begin period cash flow 141.20M 125.57M 98.71M 55.09M 85.37M
End period cash flow 92.43M 141.20M 125.57M 98.71M 55.09M
Total cash from operating activities -183.94500M -192.72700M -149.68300M 205.40M -32.25900M
Issuance of capital stock 0.00000M 0.00000M 272.16M 320.85M 0.00000M
Depreciation 20.92M 13.95M 8.47M 7.79M 6.00M
Other cashflows from investing activities - - - -470.49700M 7.05M
Dividends paid - - - - 0.00000M
Change to inventory 0.82M -5.20000M -4.99400M -1.23100M -3.04600M
Change to account receivables -22.64800M -7.36200M 2.61M -7.81700M 0.78M
Sale purchase of stock 7.89M 26.72M 293.59M 324.90M 1.27M
Other cashflows from financing activities 124.38M 27.15M 21.43M -0.93400M 1.25M
Change to netincome 56.44M 43.17M 24.83M 11.29M 9.91M
Capital expenditures 16.35M 61.75M 18.80M 11.20M 6.32M
Change receivables -22.64800M -7.36200M 2.61M - -
Cash flows other operating -46.96100M -41.16600M -42.64700M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -48.77500M 15.63M 26.86M - -
Change in working capital -71.54600M -56.81600M -40.79900M 254.93M -1.72300M
Stock based compensation 55.48M 43.25M 24.76M 13.12M 11.15M
Other non cash items 11.57M 6.95M 3.34M 0.04M 0.00500M
Free cash flow -200.29400M -254.47300M -168.48600M 194.20M -38.57700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ADPT
Adaptive Biotechnologies Corp		 0.17 1.65% 10.49 - - 5.36 4.13 4.36 -0.9991
NVO
Novo Nordisk A/S		 -2.25 2.82% 77.58 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -1.25 1.54% 79.75 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.04 0.45% 453.41 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.40 1.21% 535.64 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Adaptive Biotechnologies Corp

1165 Eastlake Avenue East, Seattle, WA, United States, 98109

Key Executives

Name Title Year Born
Mr. Chad M. Robins M.B.A, M.B.A. Co-Founder, CEO & Chairman 1974
Ms. Julie Rubinstein Pres 1972
Dr. Harlan S. Robins Ph.D. Co-Founder & Chief Scientific Officer 1973
Mr. Nitin Sood Chief Commercial Officer of MRD NA
Mr. Christopher Carlson Ph.D. Founder NA
Mr. Tycho W. Peterson Chief Financial Officer NA
Dr. Mark Adams Ph.D. Chief Operating Officer 1967
Mr. Kyle Piskel Principal Accounting Officer 1984
Yi Zhou Chief Technical Officer NA
Karina Calzadilla VP of Investor Relations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.